

In Vitro Study of Antibacterial Activity of Bidara Leaf Extract (*Ziziphus mauritiana*) against *Staphylococcus aureus* and MRSA

Muhammad Yasir Syafa'atulloh^a, Yuani Setiawati^{b*}, Wiwin Retnowati^c

*yuani-s@fk.unair.ac.id

^aMedical Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

^bDepartment of Anatomy, Histology, & Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

^cDepartment of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Abstract

Staphylococcus aureus can cause various clinical manifestations. *Staphylococcus aureus* that is resistant to methicillin, related penicillins and cephalosporins is called methicillin-resistant *Staphylococcus aureus* (MRSA). The widespread of MRSA is troublesome so a new alternative substance is needed. One of the potential alternative substance is bidara leaf (*Ziziphus mauritiana*) because it contains tannin and flavonoid. This study aimed to determine whether bidara leaf extract has antibacterial activity against *Staphylococcus aureus* and MRSA or not. The concentration of bidara leaf extract used are 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90%. Disc diffusion method was used and all tests were performed in triplicate. The data was obtained in millimeter by measuring the diameter of inhibition zone. The result for *Staphylococcus aureus* in positive control (23.67 ± 6.61 mm), negative control (0.00 ± 0.00 mm), 10% concentration (0.00 ± 0.00 mm), 20% concentration (9.09 ± 0.45 mm), 30% concentration (8.90 ± 0.06 mm), 40% concentration (9.58 ± 0.11 mm), 50% concentration (9.69 ± 0.52 mm), 60% concentration (9.98 ± 0.34 mm), 70% concentration (10.05 ± 0.92 mm), 80% concentration (9.35 ± 0.26 mm), 90% concentration (9.77 ± 0.69 mm). The result for methicillin-resistant *Staphylococcus aureus* in positive control (32.26 ± 1.93 mm), negative control (0.00 ± 0.00 mm), 10% concentration (11.25 ± 1.85 mm), 20% concentration (12.83 ± 3.47 mm), 30% concentration (13.37 ± 3.17 mm), 40% concentration (14.42 ± 3.34 mm), 50% concentration (13.44 ± 2.51 mm), 60% concentration (13.52 ± 2.24 mm), 70% concentration (16.03 ± 3.57 mm), 80% concentration (13.62 ± 2.42 mm), 90% concentration (13.06 ± 2.02 mm). Therefore, bidara leaf extract has antibacterial activity against *Staphylococcus aureus* and MRSA. The largest and smallest inhibition zone produced against both bacteria is seen at 70% concentration and 10% concentration of bidara leaf extract, respectively.

Keywords: bidara leaf extract; *Ziziphus mauritiana*; antibacterial; *Staphylococcus aureus*; MRSA

1. Introduction

Staphylococcus aureus is a coccus, Gram positive bacteria that can be found on the skin and mucous membranes of humans [1]. *Staphylococcus aureus* can cause various clinical manifestations, such as septic arthritis, skin and soft tissue infections, gastroenteritis, bacteremia, pulmonary infections, and urinary tract infections [2]. *Staphylococcus aureus* that is resistant to methicillin, related penicillins and cephalosporins is called methicillin-resistant *Staphylococcus aureus* (MRSA) [3]. Antibiotic resistance could lead to longer hospitalizations, increased mortality, and higher medical costs [4].

MRSA infection have spread to various countries in the world. In South Asia, East Asia, Western Pacific, the prevalence of MRSA varies from 2.3% to 69.1%. Furthermore, more than 60% of healthcare-associated *Staphylococcus aureus* infection in Cyprus, Portugal, Italy and Romania were identified as MRSA [5]. In the United States, MRSA infection causes 11.285 deaths per year [6]. In a study conducted in 19 countries in Asia

Pacific between 2000-2016, the prevalence of MRSA varies from 0% to 73% [7]. A study conducted in Indonesia, from 643 patients admitted to Dr. Soetomo General Hospital in Surabaya 60 MRSA isolates were detected from 52 patients [8]. In Klaten, Indonesia, a study showed that the MRSA prevalence from 2015-2018 increases from 7.69% to 12.94% [9].

The increasing number of MRSA cases and its widespread in various countries are troublesome so a new alternative substance, such as herbal, is needed. Bidara leaf is one of the herbal plants in Indonesia that contain polyphenols, tannins, and flavonoids that have antibacterial effects, such as against *Staphylococcus aureus* [10-12]. Therefore, This study aimed to determine whether bidara leaf extract has antibacterial activity against *Staphylococcus aureus* and MRSA or not.

2. Methods

2.1. Plant material

Fresh bidara leaves were collected from a bidara tree at the Institut Teknologi Sepuluh Nopember, Surabaya, Indonesia. After washed with water, collected leaves were dried in shade for about 5 days. Then, the dried leaves were sent to Assessment Service Unit of the Faculty of Pharmacy Universitas Airlangga for the extraction process.

2.2. Extraction

623 g of sample was soaked in 80% methanol with a ratio of 1:2. After 24 hours, the extract was filtered until the first filtrate was obtained. Then, the pulp of the sample was added again with 80% methanol with a ratio of 1:2. After 24 hours, the procedure number 2 and 3 were repeated to get the final filtrate for about 3 days. Then, the final filtrate was evaporated using rotary evaporator to get viscous bidara leaf extract.

2.3. Bacterial suspension

Staphylococcus aureus and MRSA from culture stock were taken by ose and were suspended into Nutrient Broth. Then, the bacterial suspension was homogenized using vortex and adjusted equivalent to 0.5 McFarland.

2.4. Antibacterial activity

The antibacterial activity of bidara leaf extract was determined using disc diffusion method. Bidara leaf extract was dissolved into 100% DMSO then the solution obtained was processed to obtain 9 concentrations (10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90%). Each bacteria were inoculated into 3 Mueller Hinton Agar Plates by sterile swabs. 100% dimethyl sulfoxide was used as negative control and Trimethoprim-Sulfamethoxazole disc (1.25 µg) was used as positive control. At 10 different places, 3 plates were perforated to be used as a place to drop 100 µl of 100% dimethyl sulfoxide (DMSO) and 100 µl of each of 9 concentration of bidara leaf extract. Trimethoprim-Sulfamethoxazole disc was placed in the remaining place of the plate. All tests were performed in triplicate. After that, all plates were incubated for 24 hours at 37°C and evaluated whether there is the inhibition zone or not. Then, the inhibition zone diameter was measured (in mm).

3. Results

3.1. *Staphylococcus aureus* inhibition zone

Table 1. The mean value of the diameter of inhibition zone (*Staphylococcus aureus*)

Group	Mean $\pm$ SD (mm)
10%	0.00 $\pm$ 0.00
20%	9.09 $\pm$ 0.45
30%	8.90 $\pm$ 0.06
40%	9.58 $\pm$ 0.11
50%	9.69 $\pm$ 0.52
60%	9.98 $\pm$ 0.34
70%	10.05 $\pm$ 0.92
80%	9.35 $\pm$ 0.26
90%	9.77 $\pm$ 0.69
Positive Control	23.67 $\pm$ 6.61
Negative Control	0.00 $\pm$ 0.00

The result of antibacterial activities of bidara leaf extract against *Staphylococcus aureus* have shown that the largest and smallest inhibition zone is produced at 70% concentration and 10% concentration, respectively. The diameter of the inhibition zone is measured by observing the transparent area where there is no bacterial growth (Fig. 1). All tests were performed in triplicate and then the mean of the 3 inhibition zone was calculated (Table 1).




Fig. 1. The inhibition zone diameter (*Staphylococcus aureus*)

Note: Ab : Trimethoprim-Sulfamethoxazole disc (positive control)
 DMSO : Dimethyl Sulfoxide (negative control)
 10 : 10% concentration

3.2. Methicillin-resistant *Staphylococcus aureus* inhibition zone

Table 2. The mean value of the diameter of inhibition zone (MRSA)

Group	Mean $\pm$ SD (mm)
10%	11.25 $\pm$ 1.85
20%	12.83 $\pm$ 3.47
30%	13.37 $\pm$ 3.17
40%	14.42 $\pm$ 3.34
50%	13.44 $\pm$ 2.51
60%	13.52 $\pm$ 2.24
70%	16.03 $\pm$ 3.57
80%	13.62 $\pm$ 2.42
90%	13.06 $\pm$ 2.02
Positive Control	32.26 $\pm$ 1.93
Negative Control	0.00 $\pm$ 0.00

The result of antibacterial activities of bidara leaf extract against methicillin-resistant *Staphylococcus aureus* have shown that the largest and smallest inhibition zone is produced at 70% concentration and 10% concentration, respectively. The diameter of the inhibition zone is measured by observing the transparent area where there is no bacterial growth (Fig. 2). All tests were performed in triplicate and then the mean of the 3 inhibition zone was calculated (Table 2).




Fig. 2. The inhibition zone diameter (MRSA)

Note: Ab : Trimethoprim-Sulfamethoxazole disc (positive control)
 DMSO : Dimethyl Sulfoxide (negative control)
 10 : 10% concentration

4. Discussion

In this study, the inhibition zone produced against *Staphylococcus aureus* in positive control (23.67 ± 6.61 mm), negative control (0.00 ± 0.00 mm), 10% concentration (0.00 ± 0.00 mm), 20% concentration (9.09 ± 0.45 mm), 30% concentration (8.90 ± 0.06 mm), 40% concentration (9.58 ± 0.11 mm), 50% concentration (9.69 ± 0.52 mm), 60% concentration (9.98 ± 0.34 mm), 70% concentration (10.05 ± 0.92 mm), 80% concentration (9.35 ± 0.26 mm), 90% concentration (9.77 ± 0.69 mm). As a comparison, a study using bidara leaf extract with 20% DMSO as a solvent could form inhibition zone with diameter of 12 mm [13]. Other study conducted in Indonesia using bidara leaf extract and 96% ethanol as a solvent tested against *Staphylococcus aureus* produced inhibition zone diameter at 1% concentration (0.00 ± 0.00 mm), 10% concentration (0.92 ± 0.056 mm), 20% concentration (1.22 ± 0.021 mm), 30% concentration (1.36 ± 0.017 mm), and 40% concentration (1.68 ± 0.03 mm) [12].

In a study of bidara leaf extract conducted in Malaysia using hexane, chloroform, and methanol as a solvent, the diameter of inhibition zone against *Staphylococcus aureus* were 15 mm, 5 mm, and 9 mm, respectively [14]. Then, in a study using silver nitrate (AgNO_3) as a solvent with concentration of 100 g/ml bidara leaf extract, from a volume of 7 μl , 14 μl , and 28 μl , the diameter of inhibition zone produced against *Staphylococcus aureus* were 8 mm, 16 mm, and 28 mm, respectively [15]. Another study of bidara leaf extract using 80% methanol as a solvent tested against *Staphylococcus aureus* produced inhibition zone diameter at concentration of 400 mg/ml (7.25 ± 0.75 mm) and 200 mg/ml (6.50 ± 0.50 mm) [16]. Then, the study conducted in Tunisia using bidara leaf extract with 70% methanol as a solvent resulted in the inhibition zone diameter of 14.2 ± 0.27 mm against *Staphylococcus aureus* [10].

In this study, the inhibition zone produced against methicillin-resistant *Staphylococcus aureus* in positive control (32.26 ± 1.93 mm), negative control (0.00 ± 0.00 mm), 10% concentration (11.25 ± 1.85 mm), 20% concentration (12.83 ± 3.47 mm), 30% concentration (13.37 ± 3.17 mm), 40% concentration (14.42 ± 3.34 mm), 50% concentration (13.44 ± 2.51 mm), 60% concentration (13.52 ± 2.24 mm), 70% concentration (16.03 ± 3.57 mm), 80% concentration (13.62 ± 2.42 mm), 90% concentration (13.06 ± 2.02 mm). As a comparison, in a study in India, the ethanolic extract of bidara leaf tested against *Staphylococcus aureus* which was resistant to several antibiotics (one of its resistance was to the methicillin). From 13 resistant *Staphylococcus aureus* isolates, the inhibition zone diameter for bidara leaf extract ranged from 10.00-12.66 mm [17]. These results were quite different from this study, in this study almost all concentrations (except at a concentration of 10%) had larger diameter.

So, the results of this study which showed that bidara leaf extract has antibacterial activity against *Staphylococcus aureus* and MRSA are supported by the various studies mentioned above. The variety of antibacterial activity produced by other studies can be attributed to the the type of solvent used, the extraction procedure, type of media used, the incubation temperature and duration, the part of the plant used and the time it was taken, the size of the inoculum, the antibacterial activity test method, and the bacterial strain used [17].

5. Conclusion

Bidara leaf extract has antibacterial activity against *Staphylococcus aureus* and MRSA. The largest and smallest inhibition zone produced against both bacteria is seen at 70% concentration and 10% concentration of bidara leaf extract, respectively.

Acknowledgements

The author would like to thank Yuani Setiawati dr., M.Ked. (yuani-s@fk.unair.ac.id) as the first supervisor and Dr. Wiwin Retnowati S.Si., M.Kes. (wiwin-r@fk.unair.ac.id) as the second supervisor for guiding author to finish this research.

References

- [1] Taylor TA, Unakal CG. Staphylococcus Aureus [Internet]. StatPearls. StatPearls Publishing; 2022. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28722898>
- [2] Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management. Clin Microbiol Rev [Internet]. 2015 Jul;28(3):603–35. Available from: <https://journals.asm.org/doi/10.1128/CMR.00134-14>
- [3] Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 9th ed. Elsevier; 2021.
- [4] World Health Organization. Antibiotic resistance [Internet]. 2020. Available from: <https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>
- [5] Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment. Crit Care [Internet]. 2017;21(1):211. Available from: <file:///pmc/articles/PMC5557425/>
- [6] Gross M. Antibiotics in crisis. Curr Biol [Internet]. 2013;23(24):R1064. Available from: <http://www.michaelgross.co.uk>
- [7] Lim WW, Wu P, Bond HS, Wong JY, Ni K, Seto WH, et al. Determinants of methicillin-resistant Staphylococcus aureus (MRSA) prevalence in the Asia-Pacific region: A systematic review and meta-analysis. J Glob Antimicrob Resist [Internet]. 2019;16:21. Available from: <file:///pmc/articles/PMC6658325/>
- [8] Kuntaman K, Hadi U, Setiawan F, Koendori EB, Rusli M, Santosaningsih D, et al. PREVALENCE OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS FROM NOSE AND THROAT OF PATIENTS ON ADMISSION TO MEDICAL WARDS OF DR SOETOMO HOSPITAL, SURABAYA, INDONESIA. Southeast Asian J Trop Med Public Health. 2016 Jan;47(1):68.
- [9] Nuryah A, Yuniarti N, Puspitasari I. Prevalensi dan Evaluasi Kesesuaian Penggunaan Antibiotik pada Pasien dengan Infeksi Methicillin Resistant Staphylococcus Aureus di RSUP Dr . Soeradji Tirtonegoro Klaten. Majalah Farmaseutik. 2019;15(2):123.
- [10] Yahia Y, Benabderrahim MA, Tlili N, Bagues M, Nagaz K. Bioactive compounds, antioxidant and antimicrobial activities of extracts from different plant parts of two Ziziphus Mill. species. PLoS One [Internet]. 2020;15(5):6–11. Available from: <http://dx.doi.org/10.1371/journal.pone.0232599>
- [11] Ashraf A, Sarfraz RA, Anwar F, Shahid SA, Alkharfy KM. Chemical composition and biological activities of leaves of Ziziphus mauritiana L. native to Pakistan. Pakistan J Bot. 2015;47(1):369–74.
- [12] Muharrami LK, Munawaroh F, Ersam T, Santoso M, Setiawan E, Hidayati Y, et al. Antibacterial Activity of Leaves Extract of Bukkol (Ziziphus mauritiana Lam) against E.coli and S.aureus. KnE Eng. 2019;1(2):182–3.
- [13] Ghasham A Al, Muzaini M Al, Qureshi KA, Elhassan GO, Khan RA, Farhana SA, et al. Phytochemical Screening , Antioxidant and Antimicrobial Activities of Methanolic Extract of Ziziphus mauritiana Lam . Leaves Collected from Unaizah , Saudi Arabia. Int J Pharm Res Allied Sci. 2017;6(3):35.
- [14] Aqilah S, Yusof M, Saat R. Phytochemical Analysis and Bioactivity Studies of Ziziphus Mauritiana (Twigs and Leaves). J Acad UiTM Negeri Sembilan. 2017;5:21.
- [15] Asimuddin M, Shaik MR, Fathima N, Afreen MS, Adil SF, Siddiqui MRH, et al. Study of Antibacterial Properties of Ziziphus mauritiana based Green Synthesized Silver Nanoparticles against Various Bacterial Strains. 2020;3–11.

- [16] Abdallah EM, Elsharkawy ER, Ed-dra A. Biological activities of methanolic leaf extract of *Ziziphus mauritiana*. 2016;9(4):606–9.
- [17] Jahan F, Lawrence R, Kumar V, Junaid M. Evaluation of antimicrobial activity of plant extracts on antibioticsusceptible and resistant *Staphylococcus aureus* strains. 2011;3(4):777–83.